Merck Clinical Trials: 2,777 Led Studies

Archive historyApr 2023 to Jul 2026

84 recorded changes across Merck trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 41 of these trials. One is shown below.

Completion date movePrimary completion moved 104 days laterNCT05853367 · recorded 16 Jul 2026

Track to read them

+80 more recorded changes · Track a drug to see every change the night it lands

Track pembrolizumab

Most active programmes

The drugs appearing most often across Merck's recently active trials. Comparator arms are excluded.

Pembrolizumab24 trials
Carboplatin14 trials
Paclitaxel13 trials
Sacituzumab tirumotecan13 trials
Rescue Medication9 trials
MK-82948 trials

Upcoming readouts

Next primary completion dates among Merck's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Jun 2027A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-724…Phase 2
Jul 2027A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembroliz…Phase 3
Jul 2027A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)Phase 3
Sept 2027A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants W…Phase 2
Oct 2027A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004…Phase 2
Oct 2027A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)Phase 3

Top therapeutic areas

Conditions studied most often across Merck's recently active trials.

Malignant Neoplasm7 trials
Non-small Cell Lung Cancer6 trials
Renal Cell Carcinoma3 trials
Non-small Cell Lung Cancer (NSCLC)3 trials
Bladder Cancer3 trials
Breast Neoplasms3 trials

Merck trials

The 50 most significant of Merck's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)NCT07348237MK-2828	Phase 1	Locked · track to reveal	OngoingRecruiting	24 est.	18 Aug 2026
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)NCT07242469MK-1403 + additive coformulation	Phase 1	Locked · track to reveal	OngoingRecruiting	52 est.	28 Aug 2026
A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)NCT07619443MK-7262	Phase 1	Not yet scored	OngoingRecruiting	30 est.	5 Sept 2026
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)NCT06442436Nemtabrutinib	Phase 1	Locked · track to reveal	OngoingRecruiting	32 est.	14 Sept 2026
A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)NCT07697625MK-4082	Phase 1	Not yet scored	OngoingNot yet recruiting	18 est.	28 Sept 2026
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)NCT06428396Belzutifan	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	120 est.	5 May 2027
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)NCT06074588Sacituzumab tirumotecan	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	556 est.	10 May 2027
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)NCT07405151I-DXd	Phase 1	Locked · track to reveal	OngoingRecruiting	60 est.	12 Jun 2027
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)NCT07133633Tulisokibart	Phase 2	Locked · track to reveal	OngoingRecruiting	315 est.	15 Jun 2027
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)NCT05093972Ulonivirine	Phase 1	Locked · track to reveal	OngoingNot yet recruiting	22 est.	29 Jun 2027
A Study of V118E in Healthy Participants (V118E-003)NCT07168915V118E	Phase 1	Locked · track to reveal	OngoingRecruiting	126 est.	6 Jul 2027
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176Sacituzumab tirumotecan	Phase 3	Locked · track to reveal	OngoingRecruiting	1,200 est.	11 Jul 2027
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)NCT07044297MK-8527	Phase 3	Locked · track to reveal	OngoingRecruiting	4,390 est.	22 Jul 2027
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)NCT06079879Bomedemstat	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	340 est.	30 Jul 2027
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)NCT05139017Zilovertamab vedotin	Phase 2	Locked · track to reveal	OngoingRecruiting	290 est.	24 Sept 2027
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)NCT06456346Bomedemstat	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	300 est.	28 Sept 2027
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)NCT07614984MK-7262	Phase 2	Locked · track to reveal	OngoingRecruiting	750 est.	12 Oct 2027
A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)NCT07071623MK-8527	Phase 3	Locked · track to reveal	OngoingRecruiting	4,580 est.	18 Oct 2027
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)NCT02861573Pembrolizumab 200 mg	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	1,200 est.	22 Oct 2027
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)NCT07463183MK-8690	Phase 2	Locked · track to reveal	OngoingRecruiting	100 est.	28 Oct 2027
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)NCT06979596Opevesostat	Phase 2	Locked · track to reveal	OngoingRecruiting	250 est.	4 Nov 2027
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)NCT06890884Zilovertamab vedotin	Phase 2	Locked · track to reveal	OngoingRecruiting	594 est.	13 Dec 2027
INTerpath-004A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).NCT06307431Intismeran autogene	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	272 est.	8 Jan 2028
AdoringA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic DermatitisNCT07265479Tapinarof cream, 1%	Phase 3	Locked · track to reveal	OngoingRecruiting	180 est.	Jan 2028
TroFuse-007Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)NCT06170788Sacituzumab tirumotecan	Phase 3	Locked · track to reveal	OngoingRecruiting	614 est.	25 Jan 2028
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)NCT02332668Pembrolizumab	Phase 1	Locked · track to reveal	OngoingRecruiting	370 est.	2 Feb 2028
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)NCT07199465Letermovir	Phase 1	Locked · track to reveal	OngoingRecruiting	40 est.	14 Apr 2028
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972Ramucirumab	Phase 1	Locked · track to reveal	OngoingRecruiting	210 est.	9 May 2028
A Study of V132 in Healthy Older Participants (V132-001)NCT07712575V132 Formulation 1	Phase 1	Not yet scored	OngoingNot yet recruiting	280 est.	21 Jun 2028
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)NCT05853367MK-0472	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	95 est.	24 Jun 2028
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737Ifinatamab deruxtecan	Phase 3	Locked · track to reveal	OngoingRecruiting	1,440 est.	26 Jun 2028
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)NCT06305754Sacituzumab tirumotecan	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	520 est.	17 Aug 2028
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)NCT06430801IV Tulisokibart	Phase 3	Locked · track to reveal	OngoingRecruiting	1,200 est.	30 Oct 2028
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)NCT07705555MK-8748	Phase 3	Not yet scored	OngoingNot yet recruiting	960 est.	31 Oct 2028
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)NCT04375800Doravirine	Phase 2	Locked · track to reveal	OngoingRecruiting	84 est.	12 Nov 2028
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)NCT07705607MK-8748	Phase 3	Not yet scored	OngoingNot yet recruiting	1,104 est.	30 Nov 2028
SOTERIAA Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)NCT07218029Sotatercept	Phase 3	Locked · track to reveal	OngoingRecruiting	815 est.	7 Dec 2028
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)NCT06596694Patritumab deruxtecan	Phase 1	Locked · track to reveal	OngoingRecruiting	180 est.	7 Dec 2028
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)NCT04728893Nemtabrutinib	Phase 2	Locked · track to reveal	OngoingRecruiting	490 est.	4 Jan 2029
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]NCT06422143Pembrolizumab	Phase 3	Locked · track to reveal	OngoingRecruiting	851 est.	12 Jan 2029
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)NCT07222488MK-3120	Phase 1	Locked · track to reveal	OngoingRecruiting	45 est.	28 Feb 2029
TroFuse-027A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)NCT06637423Sacituzumab tirumotecan	Phase 1	Locked · track to reveal	OngoingRecruiting	32 est.	14 Mar 2029
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)NCT07266831ISL	Phase 2	Locked · track to reveal	OngoingRecruiting	570 est.	21 Mar 2029
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)NCT06843447Raludotatug Deruxtecan	Phase 1	Locked · track to reveal	OngoingRecruiting	460 est.	27 Mar 2029
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)NCT06997497Calderasib	Phase 3	Locked · track to reveal	OngoingRecruiting	477 est.	28 Mar 2029
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)NCT07302347Pembrolizumab	Phase 1	Locked · track to reveal	OngoingRecruiting	20 est.	30 Mar 2029
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)NCT06824467Sacituzumab tirumotecan	Phase 3	Locked · track to reveal	OngoingRecruiting	770 est.	27 Apr 2029
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)NCT06780137Gocatamig	Phase 1	Locked · track to reveal	OngoingRecruiting	327 est.	27 Apr 2029
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)NCT07033494MK-2214	Phase 2	Locked · track to reveal	OngoingRecruiting	340 est.	30 Apr 2029
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)NCT05458297Zilovertamab vedotin	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	189 est.	17 May 2029

View all trials2,777

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)

Phase 1RecruitingNCT07242469 ↗

Primary completion: Aug 2026; estimated
Enrollment: 52; estimated
Start: Dec 2025; Merck Sharp & Dohme LLC

Conditions

Diabetes Mellitus, Type 2

Interventions

MK-1403 + additive coformulation
Placebo + additive coformulation

Brief summary

The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-1403. The study will also measure what happens to MK-1403 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Feb 2026

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)

Phase 1RecruitingNCT06442436 ↗

Primary completion: Sept 2026; estimated
Enrollment: 32; estimated
Start: Jul 2024; Merck Sharp & Dohme LLC

Conditions

Hepatic Impairment (HI)

Interventions

Nemtabrutinib

Brief summary

The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Mar 2026

Completion date move · 4

Enrollment change · 1

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Phase 2Active, not recruitingNCT06428396 ↗

Primary completion: May 2027; estimated
Enrollment: 120; estimated
Start: Nov 2024; Merck Sharp & Dohme LLC

Conditions

Metastatic Breast Cancer

Interventions

Belzutifan
Fulvestrant
Everolimus
Exemestane

Brief summary

The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-)…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jan 2025

Completion date move · 2

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Phase 3Active, not recruitingNCT06074588 ↗

Primary completion: May 2027; estimated
Enrollment: 556; estimated
Start: Nov 2023; Merck Sharp & Dohme LLC

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

Sacituzumab tirumotecan
Docetaxel
Pemetrexed

Brief summary

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jun 2026

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)

Phase 1RecruitingNCT07405151 ↗

Primary completion: Jun 2027; estimated
Enrollment: 60; estimated
Start: Mar 2026; Merck Sharp & Dohme LLC

Conditions

Oesophageal Squamous Cell Carcinoma

Interventions

I-DXd
Rescue Medication

Brief summary

The purpose of this trial is to assess if ifinatamab deruxtecan (I-DXd) can treat esophageal squamous cell carcinoma (ESCC). I-DXd is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goal of this trial is to learn how many participants…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

Phase 2RecruitingNCT07133633 ↗

Primary completion: Jun 2027; estimated
Enrollment: 315; estimated
Start: Sept 2025; Merck Sharp & Dohme LLC

Conditions

Radiographic Axial Spondyloarthritis

Interventions

Tulisokibart
Placebo

Brief summary

Researchers are looking for new ways to treat radiographic axial spondyloarthritis (r-axSpA). R-axSpA is a type of arthritis that causes pain, stiffness, and inflammation (swelling) in the spine and joints in the pelvis (hip bone). Radiographic means the damage it causes can be seen on X-rays. This study will help…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Nov 2025

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)

Phase 1Not yet recruitingNCT05093972 ↗

Primary completion: Jun 2027; estimated
Enrollment: 22; estimated
Start: Jan 2027; Merck Sharp & Dohme LLC

Conditions

Hepatic Insufficiency

Interventions

Ulonivirine

Brief summary

The purpose of this study is to evaluate pharmacokinetics (PK) and safety of a single oral dose of ulonivirine in participants with mild or moderate hepatic impairment (HI). It is hypothesized that the area under the plasma concentration-time curve from dosing to (extrapolated) infinity (AUC0-∞) in participants with…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Apr 2025

Completion date move · 4

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Phase 3RecruitingNCT06312176 ↗

Primary completion: Jul 2027; estimated
Enrollment: 1,200; estimated
Start: Apr 2024; Merck Sharp & Dohme LLC

Conditions

Breast Neoplasms

Interventions

Sacituzumab tirumotecan
Pembrolizumab
Paclitaxel
Nab-paclitaxel
Capecitabine
Liposomal doxorubicin

Brief summary

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jul 2024

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Phase 3RecruitingNCT07044297 ↗

Primary completion: Jul 2027; estimated
Enrollment: 4,390; estimated
Start: Jul 2025; Merck Sharp & Dohme LLC

Conditions

Human Immunodeficiency Virus (HIV)
HIV Pre-Exposure Prophylaxis

Interventions

MK-8527
FTC/TDF
Placebo to MK-8527
Placebo to FTC/TDF

Brief summary

Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection as well as or better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Dec 2025

Completion date move · 1

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Phase 3Active, not recruitingNCT06079879 ↗

Primary completion: Jul 2027; estimated
Enrollment: 340; estimated
Start: Dec 2023; Merck Sharp & Dohme LLC

Conditions

Essential Thrombocythemia

Interventions

Bomedemstat
Anagrelide
Busulfan
Interferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2b
Ruxolitinib

Brief summary

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Dec 2025

Completion date move · 1

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Phase 2RecruitingNCT05139017 ↗

Primary completion: Sept 2027; estimated
Enrollment: 290; estimated
Start: Jan 2022; Merck Sharp & Dohme LLC

Conditions

DLBCL
Diffuse Large B-Cell Lymphoma

Interventions

Zilovertamab vedotin
Rituximab
Gemcitabine
Oxaliplatin
Bendamustine
Granulocyte Colony-Stimulating Factor (G-CSF)

Brief summary

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1)…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jan 2025

Completion date move · 3

Enrollment change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Phase 3Active, not recruitingNCT06456346 ↗

Primary completion: Sept 2027; estimated
Enrollment: 300; estimated
Start: Jul 2024; Merck Sharp & Dohme LLC

Conditions

Essential Thrombocythemia

Interventions

Bomedemstat
Hydroxyurea
Bomedemstat placebo
Hydroxyurea placebo

Brief summary

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreductive therapy is indicated. Its primary objective is to compare bomedemstat to hydroxyurea with respect to durable…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Nov 2025

Completion date move · 2

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Phase 3RecruitingNCT07071623 ↗

Primary completion: Oct 2027; estimated
Enrollment: 4,580; estimated
Start: Nov 2025; Merck Sharp & Dohme LLC

Conditions

Human Immunodeficiency Virus (HIV)
HIV Pre-Exposure Prophylaxis

Interventions

MK-8527
Emtricitabine/tenofovir disoproxil (FTC/TDF)
Placebo matched to MK-8527
Placebo matched to FTC/TDF

Brief summary

Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection. The goals of this study are to learn: * If taking MK-8527 once a month works to prevent HIV-1 infection better than a standard (usual) pre-exposure prophylaxis (PrEP) taken once a day * About the safety of…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Dec 2025

Status change · 1

Completion date move · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Phase 1Active, not recruitingNCT02861573 ↗

Primary completion: Oct 2027; estimated
Enrollment: 1,200; estimated
Start: Nov 2016; Merck Sharp & Dohme LLC

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

Pembrolizumab 200 mg
Olaparib 400 mg
Docetaxel 75 mg/m^2
Prednisone 5 mg
Enzalutamide 160 mg
Dexamethasone 8 mg
Olaparib 300 mg
Abiraterone acetate 1000 mg

Brief summary

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab +…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Oct 2023

Completion date move · 1

Enrollment change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

Phase 2RecruitingNCT07463183 ↗

Primary completion: Oct 2027; estimated
Enrollment: 100; estimated
Start: Mar 2026; Merck Sharp & Dohme LLC

Conditions

Colitis Ulcerative
Ulcerative Colitis

Interventions

MK-8690
Placebo

Brief summary

The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 May 2026

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

Phase 2RecruitingNCT06979596 ↗

Primary completion: Nov 2027; estimated
Enrollment: 250; estimated
Start: Aug 2025; Merck Sharp & Dohme LLC

Conditions

Malignant Neoplasm

Interventions

Opevesostat
Fludrocortisone/ Fludrocortisone acetate
Dexamethasone/Dexamethasone acetate
Rescue Medications
Fulvestrant
Exemestane
Megestrol acetate/Medroxyprogesterone acetate
Tamoxifen

Brief summary

Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones. Researchers will compare MK-5684 to the standard treatments for each cancer type in…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Sept 2025

Completion date move · 1

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Phase 2RecruitingNCT06890884 ↗

Primary completion: Dec 2027; estimated
Enrollment: 594; estimated
Start: Apr 2025; Merck Sharp & Dohme LLC

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

Zilovertamab vedotin
Rituximab
Cyclophosphamide
Doxorubicin
Rituximab Biosimilar
Prednisone
Prednisolone
Polatuzumab vedotin

Brief summary

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jul 2025

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

INTerpath-004: A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

Phase 2Active, not recruitingNCT06307431 ↗

Primary completion: Jan 2028; estimated
Enrollment: 272; estimated
Start: Apr 2024; Merck Sharp & Dohme LLC

Conditions

Renal Cell Carcinoma

Interventions

Intismeran autogene
Pembrolizumab
Placebo

Brief summary

The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intismeran autogene plus pembrolizumab is…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2025

Status change · 2

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

TroFuse-007: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Phase 3RecruitingNCT06170788 ↗

Primary completion: Jan 2028; estimated
Enrollment: 614; estimated
Start: Dec 2023; Merck Sharp & Dohme LLC

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

Sacituzumab tirumotecan
Pembrolizumab
Supportive care measures

Brief summary

The primary objective of the study is to compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS). The primary hypothesis is that the combination of sacituzumab tirumotecan and pembrolizumab is superior to pembrolizumab alone with respect to OS. All…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2024

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Phase 1RecruitingNCT02332668 ↗

Primary completion: Feb 2028; estimated
Enrollment: 370; estimated
Start: Mar 2015; Merck Sharp & Dohme LLC

Conditions

Melanoma
Lymphoma
Solid Tumor
Classical Hodgkin Lymphoma
Microsatellite-instability-high Solid Tumor

Interventions

Pembrolizumab

Brief summary

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jun 2026

Completion date move · 2

Enrollment change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

Phase 1RecruitingNCT07199465 ↗

Primary completion: Apr 2028; estimated
Enrollment: 40; estimated
Start: Mar 2026; Merck Sharp & Dohme LLC

Conditions

Cytomegalovirus Prophylaxis

Interventions

Letermovir

Brief summary

Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds). The goals of the study are to: * Learn what happens to letermovir in the body over time * Learn about the safety of letermovir and if…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Nov 2025

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Phase 1RecruitingNCT06445972 ↗

Primary completion: May 2028; estimated
Enrollment: 210; estimated
Start: Aug 2024; Merck Sharp & Dohme LLC

Conditions

Gastroesophageal Junction
Gastroesophageal Adenocarcinoma
Esophageal Neoplasms
Esophageal Cancer

Interventions

Ramucirumab
Paclitaxel
Sacituzumab Tirumotecan
Rescue Medications
HER3-DXd

Brief summary

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, and HER3-DXD plus ramucirumab versus ramucirumab plus paclitaxel for the treatment of participants with advanced or…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Apr 2026

Completion date move · 1

Enrollment change · 1

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Phase 1Active, not recruitingNCT05853367 ↗

Primary completion: Jun 2028; estimated
Enrollment: 95; estimated
Start: Jul 2023; Merck Sharp & Dohme LLC

Conditions

Metastatic Solid Tumors
Advanced Solid Tumors

Interventions

MK-0472
Pembrolizumab
MK-1084

Brief summary

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 16 Jul 2026

Enrollment change · 2

Completion date move · 1

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Phase 3Active, not recruitingNCT06305754 ↗

Primary completion: Aug 2028; estimated
Enrollment: 520; estimated
Start: Jun 2024; Merck Sharp & Dohme LLC

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

Sacituzumab tirumotecan
Pemetrexed
Carboplatin
H1 Receptor Antagonist
H2 Receptor Antagonist
Acetaminophen (or equivalent)
Dexamethasone (or equivalent)
Steroid Mouthwash (dexamethasone or equivalent)

Brief summary

The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jun 2026

Status change · 2

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Phase 3RecruitingNCT06430801 ↗

Primary completion: Oct 2028; estimated
Enrollment: 1,200; estimated
Start: Jun 2024; Merck Sharp & Dohme LLC

Conditions

Crohn's Disease

Interventions

IV Tulisokibart
SC Tulisokibart
IV Placebo
SC Placebo

Brief summary

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2025

Completion date move · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Phase 2RecruitingNCT04375800 ↗

Primary completion: Nov 2028; estimated
Enrollment: 84; estimated
Start: Feb 2021; Merck Sharp & Dohme LLC

Conditions

Human Immunodeficiency Virus (HIV) Infection

Interventions

Doravirine
2 NRTIs
DOR/3TC/TDF

Brief summary

This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Mar 2026

Completion date move · 2

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

SOTERIA: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

Phase 3RecruitingNCT07218029 ↗

Primary completion: Dec 2028; estimated
Enrollment: 815; estimated
Start: May 2021; Merck Sharp & Dohme LLC

Conditions

Pulmonary Arterial Hypertension

Interventions

Sotatercept

Brief summary

Researchers are looking for more ways to treat PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow. This causes high blood pressure in the lungs and overworks the heart. PAH can make it hard to breathe and be active. Some standard (usual) treatments for PAH can…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2026

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)

Phase 1RecruitingNCT06596694 ↗

Primary completion: Dec 2028; estimated
Enrollment: 180; estimated
Start: Nov 2024; Merck Sharp & Dohme LLC

Conditions

Gastrointestinal Cancer

Interventions

Patritumab deruxtecan

Brief summary

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan *…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Dec 2025

Completion date move · 1

Enrollment change · 1

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Phase 2RecruitingNCT04728893 ↗

Primary completion: Jan 2029; estimated
Enrollment: 490; estimated
Start: Apr 2021; Merck Sharp & Dohme LLC

Conditions

Hematologic Malignancies
Waldenstroms Macroglobulinaemia
Non-Hodgkins Lymphoma
Chronic Lymphocytic Leukaemia

Interventions

Nemtabrutinib

Brief summary

The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2026

Completion date move · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Phase 3RecruitingNCT06422143 ↗

Primary completion: Jan 2029; estimated
Enrollment: 851; estimated
Start: Jun 2024; Merck Sharp & Dohme LLC

Conditions

Non-small Cell Lung Cancer
NSCLC

Interventions

Pembrolizumab
sac-TMT
Carboplatin
Paclitaxel
Nab-paclitaxel

Brief summary

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

TroFuse-027: A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Phase 1RecruitingNCT06637423 ↗

Primary completion: Mar 2029; estimated
Enrollment: 32; estimated
Start: Dec 2024; Merck Sharp & Dohme LLC

Conditions

Non-Muscle Invasive Bladder Cancer

Interventions

Sacituzumab tirumotecan
Rescue medication
Supportive care measures

Brief summary

The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use in future studies to learn…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2025

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Phase 2RecruitingNCT07266831 ↗

Primary completion: Mar 2029; estimated
Enrollment: 570; estimated
Start: Dec 2025; Merck Sharp & Dohme LLC

Conditions

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Interventions

ISL
ULO
BIC/FTC/TAF
Placebo for BIC/FTC/TAF
Placebo to ISL/ULO
ISL/ULO

Brief summary

Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Completion date move · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Phase 1RecruitingNCT06843447 ↗

Primary completion: Mar 2029; estimated
Enrollment: 460; estimated
Start: Apr 2025; Merck Sharp & Dohme LLC

Conditions

Ovarian Cancer Recurrent

Interventions

Raludotatug Deruxtecan
Carboplatin
Paclitaxel
Bevacizumab
Rescue Medication
Pembrolizumab
Gemcitabine
Pegylated liposomal doxorubicin

Brief summary

Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jun 2026

Enrollment change · 2

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

Phase 3RecruitingNCT06997497 ↗

Primary completion: Mar 2029; estimated
Enrollment: 477; estimated
Start: Jul 2025; Merck Sharp & Dohme LLC

Conditions

Colon Adenocarcinoma
Rectal Adenocarcinoma

Interventions

Calderasib
Oxaliplatin
Leucovorin/levofolinate calcium
5-Fluorouracil
Cetuximab
Bevacizumab
Bevacizumab biosimilar

Brief summary

Researchers are looking for other ways to treat locally advanced or metastatic colorectal cancer (mCRC) that is unresectable and has a gene mutation called KRAS G12C. Standard (or usual) treatments for this type of colorectal cancer may include mFOLFOX6 with or without bevacizumab. Researchers want to learn if adding…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jan 2026

Completion date move · 1

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

Phase 1RecruitingNCT07302347 ↗

Primary completion: Mar 2029; estimated
Enrollment: 20; estimated
Start: Jun 2026; Merck Sharp & Dohme LLC

Conditions

Malignant Neoplasm
Carcinoma, Merkel Cell
Lymphoma

Interventions

Pembrolizumab

Brief summary

Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn: * About the safety of pembrolizumab (the study medicine) and if people tolerate it * What happens to different doses of pembrolizumab in a…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Phase 3RecruitingNCT06824467 ↗

Primary completion: Apr 2029; estimated
Enrollment: 770; estimated
Start: Apr 2025; Merck Sharp & Dohme LLC

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions

Sacituzumab tirumotecan
Bevacizumab
H1 receptor antagonist
H2 receptor antagonist
Acetaminophen (or equivalent)
Dexamethasone (or equivalent)
Steroid mouthwash (dexamethasone or equivalent)

Brief summary

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Phase 1RecruitingNCT06780137 ↗

Primary completion: Apr 2029; estimated
Enrollment: 327; estimated
Start: Feb 2025; Merck Sharp & Dohme LLC

Conditions

Small Cell Lung Cancer

Interventions

Gocatamig
Ifinatamab Deruxtecan (I-DXd)
Durvalumab

Brief summary

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a drug which binds to…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Aug 2025

Enrollment change · 1

Completion date move · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Phase 2RecruitingNCT07033494 ↗

Primary completion: Apr 2029; estimated
Enrollment: 340; estimated
Start: Jul 2025; Merck Sharp & Dohme LLC

Conditions

Early Alzheimer's Disease

Interventions

MK-2214
Placebo

Brief summary

Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks.…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Aug 2025

Status change · 1

Completion date move · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

Phase 2Active, not recruitingNCT05458297 ↗

Primary completion: May 2029; estimated
Enrollment: 189; estimated
Start: Jul 2022; Merck Sharp & Dohme LLC

Conditions

Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Follicular Lymphoma
Richter Transformation Lymphoma

Interventions

Zilovertamab vedotin
Nemtabrutinib

Brief summary

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jun 2026

Enrollment change · 2

Completion date move · 2

Status change · 1

Track Merck drugs to see every change the night it lands.

Track pembrolizumab